IMMATICS N.V. revenue breakdown overview

IMMATICS N.V. revenue for the last year amounted to 54.00 M EUR, the most of which — 52.89 M EUR — came from its highest performing source at the moment, T Cell Redirecting Immunotherapies, the year earlier bringing 169.72 M EUR. The greatest contribution to the revenue figure was made by Germany — last year it brought IMMATICS N.V. 52.89 M EUR, and the year before that — 169.72 M EUR.